SHAILY Q4 FY26 Guidance vs Delivery (SHAILY Management Mirror)

Healthcare Volumes & Capacity

Management expects to produce ~36 million pens in FY27 and ~50 million in FY28, aiming for 40-60 million pen capacity utilization by FY28 across semaglutide and insulin; this follows the Sep'25 Qtr plan to double capacity to 80 million pens and the Dec'25 Qtr guidance of supplying ~30 million pens despite minor qualification delays, with the latest quarter noting that new lines installed by August should push effective combined capacity to 40-42 million pens this year. [Status: Reaffirmed]